Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation

Anesthesiology

Volumn 120, Issue 6, 2014, Pages 1429-1440

  Van Ryn, Joanne ^a   Schurer, Johanna ^a   Kink Eiband, Monika ^a   Clemens, Andreas ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 9 COMPLEX; DABIGATRAN ETEXILATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; CONCENTRATION RESPONSE; DRUG EFFECT; HUMAN; IN VITRO STUDY; NONHUMAN; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBIN TIME;

ANIMALS; BENZIMIDAZOLES; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DISEASE MODELS, ANIMAL; HEMORRHAGE; HUMANS; PYRIDINES; RATS; RATS, WISTAR; TAIL; TREATMENT OUTCOME;

EID: 84901602200     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000255     Document Type: Article

References (53)

1. Weitz JI, Quinlan DJ, Eikelboom JW: Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012; 126:2428-32
2. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U: A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19:446-51
3. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T: A specific antidote for dabigatran: Functional and structural characterization. Blood 2013; 121:3554-62
4. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J: Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87(suppl 1):S141-5
5. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B: Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 2008; 83:137-43
6. Patanwala AE, Acquisto NM, Erstad BL: Prothrombin complex concentrate for critical bleeding. Ann Pharmacother 2011; 45:990-9
7. Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:542-7
8. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J: Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10:1841-8
9. Bebulin VH, Factor IX Complex Package Insert. Westlake Village, Baxter Healthcare, April 2011
10. Profilnine SD, Factor IX Complex Package Insert. Los Angeles, Grifols Biologicals Inc., January 2013
11. Beriplex P/N (Human Prothrombin Complex) Summary of Product Characteristics. Marburg, Germany, CSL Behring GmbH, November 2012
12. Octaplex (Human Prothrombin Complex) Summary of Product Characteristics. Lachen, Switzerland, Octapharma AG, May 11, 2010
13. NovoSeven (Recombinant Coagulation Factor VIIa) Summary of Product Characteristics. Bagsvard, Denmark, Novo Nordisk A/S, 2010
14. FEIBA NF, Anti-inhibitor Coagulant Complex Package Insert. Westlake Village, Baxter Healthcare, February 2011
15. Gustafsson D, Elg M, Lenfors S, Börjesson I, Teger-Nilsson AC: Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis 1996; 7:69-79
16. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N: Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007; 98:333-8
17. Stangier J, Feuring M: Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23:138-43
18. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4-15
19. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-27
20. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A: Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9:2168-75
21. Lassila R, Munsterhjelm E, Joutsi-Korhonen L, Armstrong E: Laboratory follow-up and clinical management of a patient case with severe bleeding complication on dabigatran for atrial fibrillation (abstract P-TH-227). J Thromb Haemost 2011; 9(suppl 2):129-30
22. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, Drouet L, Payen D: The use of dabigatran in elderly patients. Arch Intern Med 2011; 171:1285-6
23. Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, Samama MM: Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation. Thromb Haemost 2012; 108:583-5
24. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-9
25. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R: Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42:3594-9
26. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T: Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012; 107:253-9
27. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM: Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116:94-102
28. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G: Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108:217-24
29. Pillitteri D, Pilgrimm-Thorp AK, Krause M, Scholz T, Schwerdtfeger R, Behrendt T, Kirchmaier C: Antidotal effects of non-specific reversal agents on anticoagulant-induced inhibition of thrombin generation (abstract). Blood 2012; 120:2273
30. Galan AM, Arellano-Rodrigo E, Sanz VV, Molina P, Reverter JC, Carne X, Villalta J, Tassies D, Diaz-Ricart M, Escolar G: Reversal of the antithrombotic action of rivaroxaban and dabigatran: A clinical study in healthy volunteers (abstract). Blood 2012; 120:2261
31. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP: Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012; 10:1830-40
32. Zhou W, Zorn M, Nawroth P, Bütehorn U, Perzborn E, Heitmeier S, Veltkamp R: Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44:771-8
33. Perzborn E, Gruber A, Tinel H, Marzec UM, Buetehorn U, Buchmueller A, Heitmeier S, Laux V: Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110:162-72
34. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A: In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost 2013; 11:1111-8
35. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A: Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013; 168:4228-33
36. Jeske W, Iqbal O, Fareed J, Kaiser B: A survey of animal models to develop novel antithrombotic agents, New Therapeutic Agents in Thrombosis and Thrombolysis, 2nd edition. Edited by Sasahara A, Loscalzo J. Boston, Marcel Dekker Inc., 2003, pp 9-32
37. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN: Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128:1234-43
38. Grottke O, Rossaint R, Henskens Y, van Oerle R, Ten Cate H, Spronk HM: Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model. PLoS One 2013; 8:e64100
39. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S: The use of FEIBAR in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013; 35:222-4
40. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW: Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119:2172-4
41. Mastrobuoni S, Robblee JA, Boodhwani M: Spontaneous ascending aortic intramural haematoma in a patient on dabigatran. Interact Cardiovasc Thorac Surg 2012; 15: 299-300
42. Coufal F, Tominaga G, Wallach S, Schaffer K: A case study of dabigatran-induced coagulopathy with bilateral subdural hematomas after remote trauma with subsequent hypercoagulable complications in a 76 year old male with paroxysmal atrial fibrillation-Management without effective reversal strategy available (abstract 0788). Brain Injury 2012; 26:722-3
43. Dumkow LE, Voss JR, Peters M, Jennings DL: Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 2012; 69:1646-50
44. Wychowski MK, Kouides PA: Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46:e10
45. Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, Hoffman RS, Nelson LS: Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 2012; 50:854-7
46. Cano EL, Miyares MA: Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012; 10:160-3
47. Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J: Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine (Phila Pa 1976) 2012; 37:E863-5
48. Harinstein LM, Morgan JW, Russo N: Treatment of dabigatran-associated bleeding: Case report and review of the literature. J Pharm Pract 2013; 26:264-9
49. Kamboj J, Kottalgi M, Cirra VR, Shah N, Kamboj R: Direct thrombin inhibitors: A case indicating benefit from 'plasmapheresis' in toxicity: A call for establishing "guidelines" in overdose and to find an "antidote"! Am J Ther 2012; 19:e182-5
50. Dager WE, Gosselin RC, Roberts AJ: Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013; 41:e42-6
51. Petersen LC, Nørby PL, Branner S, Sørensen BB, Elm T, Stennicke HR, Persson E, Bjørn SE: Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: A human-murine species compatibility study. Thromb Res 2005; 116:75-85
52. Mackman N: Tissue-specific hemostasis: Role of tissue factor. J Thromb Haemost 2008; 6:303-5
53. Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock WA Jr, Triplett DA, Brandt JT: The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133:134-9